{"id":"eu-avastin","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Hypertension"},{"rate":"20–25%","effect":"Proteinuria"},{"rate":"15–20%","effect":"Hemorrhage (all grades)"},{"rate":"10–15%","effect":"Thromboembolism"},{"rate":"1–2%","effect":"Gastrointestinal perforation"},{"rate":"5–10%","effect":"Wound healing complications"},{"rate":"15–20%","effect":"Fatigue"},{"rate":"10–15%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5857501","moleculeType":null,"molecularWeight":"542.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab binds to circulating VEGF, preventing its interaction with VEGF receptors on endothelial cells. This inhibits angiogenesis—the formation of new blood vessels that tumors require for growth and metastasis. By starving tumors of their blood supply, the drug reduces tumor progression and improves survival in combination with chemotherapy or other targeted agents.","oneSentence":"Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor blood vessel formation and slow cancer growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:46.918Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with chemotherapy)"},{"name":"Metastatic non-small cell lung cancer (in combination with chemotherapy)"},{"name":"Metastatic breast cancer (in combination with chemotherapy)"},{"name":"Glioblastoma (recurrent)"},{"name":"Metastatic renal cell carcinoma (in combination with interferon-alpha)"}]},"trialDetails":[{"nctId":"NCT06232902","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-06-20","conditions":"Tumor","enrollment":84},{"nctId":"NCT03390673","phase":"PHASE1","title":"To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects","status":"COMPLETED","sponsor":"Prestige Biopharma Limited","startDate":"2018-09-19","conditions":"Healthy Volunteers","enrollment":119},{"nctId":"NCT04238663","phase":"PHASE1","title":"Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2019-09-24","conditions":"Healthy Volunteers","enrollment":115},{"nctId":"NCT05427305","phase":"PHASE3","title":"TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"BioDlink Biopharm Co., Ltd.","startDate":"2017-10-20","conditions":"Efficacy","enrollment":549},{"nctId":"NCT03483649","phase":"PHASE1","title":"Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-04-21","conditions":"Healthy Male Subjects","enrollment":208},{"nctId":"NCT02469987","phase":"PHASE1","title":"Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-04","conditions":"Healthy","enrollment":111},{"nctId":"NCT03329911","phase":"PHASE3","title":"A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2017-10-20","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":651},{"nctId":"NCT03296163","phase":"PHASE3","title":"A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2018-02-06","conditions":"Non-small Cell Lung Cancer","enrollment":627},{"nctId":"NCT03293654","phase":"PHASE1","title":"A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2017-12-07","conditions":"Healthy Volunteers","enrollment":114},{"nctId":"NCT04238650","phase":"PHASE1","title":"A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2019-08-02","conditions":"Healthy Volunteers, Male, Japanese","enrollment":49},{"nctId":"NCT01984242","phase":"PHASE2","title":"A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-08","conditions":"Renal Cell Carcinoma","enrollment":305},{"nctId":"NCT02453672","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2015-04","conditions":"Healthy","enrollment":119},{"nctId":"NCT03030430","phase":"PHASE1","title":"Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2016-03-15","conditions":"NSCLC","enrollment":128},{"nctId":"NCT03131700","phase":"PHASE1","title":"Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator","status":"WITHDRAWN","sponsor":"TRPHARM","startDate":"2017-12","conditions":"Healthy","enrollment":""},{"nctId":"NCT02747823","phase":"PHASE1","title":"PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)","status":"UNKNOWN","sponsor":"Cipla BioTec Pvt. Ltd.","startDate":"2016-06","conditions":"Healthy","enrollment":150},{"nctId":"NCT02879097","phase":"PHASE3","title":"Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC","status":"UNKNOWN","sponsor":"Cipla BioTec Pvt. Ltd.","startDate":"2016-12","conditions":"Non-Small Cell Lung Carcinoma","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"EU Avastin®","genericName":"EU Avastin®","companyName":"Bio-Thera Solutions","companyId":"bio-thera-solutions","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor blood vessel formation and slow cancer growth. Used for Metastatic colorectal cancer (in combination with chemotherapy), Metastatic non-small cell lung cancer (in combination with chemotherapy), Metastatic breast cancer (in combination with chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}